Investment
Features
FeesSafety
Academy
More
Pluang+

Compare TransMedics Group Inc (TMDX) vs WD 40 Company (WDFC) Price & Performance

TransMedics Group IncTrade
WD 40 CompanyTrade

Price performance (Past 24H)

Key statistics

TransMedics Group Inc vs WD 40 Company — how do they compare? TransMedics Group Inc trades at $87.08 (market cap $3.10B), while WD 40 Company trades at $231.66 (market cap $3.13B). The key difference: TransMedics Group Inc and WD 40 Company are close in size by market cap, and WD 40 Company pays a 1.75% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

TMDXWDFC
Market Cap
$3.10B$3.13B
Sector
TechnologyTechnology
52-Week High
$150.42$264.91
52-Week Low
$61.99$187.52
Enterprise Value
$3.49B$3.18B
Dividend Yield
1.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.

The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.

WD 40 Company

WDFC trades at $232.50, down 0.86% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $2.33 per share, beating estimates, but faces gross margin pressure from input costs. Revenue is projected to grow to $675 million in 2026, though net income may dip slightly. A dividend of $1.02 per share is payable July 31, 2026.

Outlook is mixed: solid brand strength and cash flow support stability, but high valuation ratios and margin pressures pose risks. Analyst consensus is cautious with 71% hold ratings. Key catalysts include execution against growth strategy, while headwinds include cost inflation and competitive challenges.

Returns comparison

Trailing returns across standard periods

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX

About WD 40 Company

WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.

Read more on WDFC